ModernVivo
New drugs fail in human clinical trials 90% of the time. These failures can be traced directly back to the consistent inability of preclinical animal studies to predict clinical success. Yet the design process for preclinical animal studies has remained largely unchanged for decades; scientists read a tiny fraction of published literature and write their experimental protocols in 2-4 weeks. This time-consuming, tedious process is not only a major pain point for in-vivo scientists but leads to substantial experimental design flaws, resulting in unreliable data with which billion-dollar decisions are made. Scientists we’ve spoken to repeatedly express their struggle with the overwhelming amount of preclinical information they need to sift through in order to design experiments. At ModernVivo, we are revolutionizing this antiquated process by equipping scientists with tools that enable them to write in-vivo protocols more effectively. Our technology empowers scientists to streamline their work, accelerating drug development timelines.
New drugs fail in human clinical trials 90% of the time. These failures can be traced directly back to the consistent inability of preclinical animal studies to predict clinical success. Yet the design process for preclinical animal studies has remained largely unchanged for decades; scientists read a tiny fraction of published literature and write their experimental protocols in 2-4 weeks. This time-consuming, tedious process is not only a major pain point for in-vivo scientists but leads to substantial experimental design flaws, resulting in unreliable data with which billion-dollar decisions are made. Scientists we’ve spoken to repeatedly express their struggle with the overwhelming amount of preclinical information they need to sift through in order to design experiments. At ModernVivo, we are revolutionizing this antiquated process by equipping scientists with tools that enable them to write in-vivo protocols more effectively. Our technology empowers scientists to streamline their work, accelerating drug development timelines.
ModernVivo has raised $20k across 1 round. Its most recent round was a Series Unknown of $20k in Aug 2023. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
ModernVivo is featured in
Similar companies
Verisoul is a company that designs a decentralized platform with artificial intelligence, aiming to aid businesses in combating the presence of fraudulent users. By merging anonymity and accountability, Verisoul collaborates with Web3 developers to enable them in identifying reliable users while distinguishing them from scammers, bots, and imposters.
Model ML is an AI tool that improves workflows for investment banks and private equity firms by integrating multiple data sources for research and due diligence, with the goal of revolutionizing the finance industry with a more efficient AI workspace.
Apptronik fabricates and plans human-focused mechanical technology frameworks.
Momentic allows developers to deploy AI agents to test the complete functionality of web applications by simply describing user flows in a natural language.
The company Harmonic creates Mathematical Superintelligence (MSI), a cutting-edge artificial intelligence system grounded in mathematical principles to ensure precision and eliminate errors.
Scale Social is an AI-powered marketing platform that automates capturing, curating, and distributing customer-generated content. It is specifically designed to help small businesses drive growth through authentic, high-impact digital marketing.
Federato's RiskOps underwriting platform for insurance carriers, MGAs and MGUs provides real-time risk selection and portfolio insights to empower underwriters to balance their book of business and make better underwriting decisions.
Kalshi is a financial exchange that is regulated by the government and allows investors to trade based on their predictions of future events. The markets offered by Kalshi cover various topics such as economics, international affairs, media, entertainment, climate, and public health. Unlike traditional instruments like stocks or bonds, Kalshi's markets are more specific, giving investors direct exposure to events and trends they are interested in. For example, a market on the signing of a free trade agreement can help retail investors gain exposure to emerging markets and changes in international trade. Check out their website at https://kalshi.com.
Suno is a music startup that allows individuals to create the music they desire, with the goal of helping people find pleasure in play and discovery once again.
Organizations trust Numeric to guarantee the accuracy of their financial information, streamline the month-end closing process, and provide immediate insights. With a rating of 4.9 out of 5 on G2.
AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Luma is an AI company building the future of 3D.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.